130 related articles for article (PubMed ID: 17486433)
1. Memory enhancing drugs and Alzheimer's disease: enhancing the self or preventing the loss of it?
Dekkers W; Rikkert MO
Med Health Care Philos; 2007 Jun; 10(2):141-51. PubMed ID: 17486433
[TBL] [Abstract][Full Text] [Related]
2. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Brousseau G; Rourke BP; Burke B
Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Alzheimer's disease with cholinergic drugs.
Kumar V; Calache M
Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):23-37. PubMed ID: 2004862
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's dementia: current data review.
Uzun S; Kozumplik O; Folnegović-Smalc V
Coll Antropol; 2011 Dec; 35(4):1333-7. PubMed ID: 22397284
[TBL] [Abstract][Full Text] [Related]
5. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
Popp J; Arlt S
Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
[TBL] [Abstract][Full Text] [Related]
7. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
Törmälehto SM; Martikainen JA; Väätäinen ST; Hallikainen IT; Hallikainen M; Bell JS; Koivisto AM
J Alzheimers Dis; 2015; 48(4):1033-41. PubMed ID: 26444756
[TBL] [Abstract][Full Text] [Related]
8. [Acetylcholinesterase inhibitors for treatment of Alzheimer's disease].
Shinagawa S; Shigeta M
Brain Nerve; 2014 May; 66(5):507-16. PubMed ID: 24807367
[TBL] [Abstract][Full Text] [Related]
9. [Drug therapy for Alzheimer's disease].
Shoji M
Brain Nerve; 2010 Jul; 62(7):777-85. PubMed ID: 20675882
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
Tayeb HO; Yang HD; Price BH; Tarazi FI
Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
[TBL] [Abstract][Full Text] [Related]
11. Research design issues: antialuminum drug studies in Alzheimer's disease.
Shore D; Wyatt RJ
Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
[TBL] [Abstract][Full Text] [Related]
12. [Present trends in the development of drugs within the cholinesterase inhibitor group as therapeutic agents for Alzheimer's disease].
Patocka J; Fusek J
Cesk Psychiatr; 1992 Sep; 88(5):258-69. PubMed ID: 1451205
[TBL] [Abstract][Full Text] [Related]
13. NICE says anti-dementia drugs should be used only for moderate Alzheimer's disease.
Day M
BMJ; 2006 Oct; 333(7572):774. PubMed ID: 17038731
[No Abstract] [Full Text] [Related]
14. Herbal medicine in the treatment of Alzheimer's disease.
Akhondzadeh S; Abbasi SH
Am J Alzheimers Dis Other Demen; 2006; 21(2):113-8. PubMed ID: 16634467
[TBL] [Abstract][Full Text] [Related]
15. Anti-dementia drugs and hippocampal-dependent memory in rodents.
Yuede CM; Dong H; Csernansky JG
Behav Pharmacol; 2007 Sep; 18(5-6):347-63. PubMed ID: 17762506
[TBL] [Abstract][Full Text] [Related]
16. Mild cognitive impairment and preclinical Alzheimer's disease.
Morris JC
Geriatrics; 2005 Jun; Suppl():9-14. PubMed ID: 16025770
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Schölzel-Dorenbos CJ;
Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
20. [Intended pharmacotherapeutical approaches of Alzheimer's disease therapy].
Korábecný J; Hrubá E; Soukup O; Zemek F; Musílek K; Nepovímová E; Spilovská K; Opletalová V; Kuca K
Ceska Slov Farm; 2012 Feb; 61(1-2):4-10. PubMed ID: 22536646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
